HAL
40
11
EMR
57
7
WBA
41
3
ADT
12
2
D
32
10
INTU
54
2
MU
42
14
JNPR
59
3
PLD
35
5
OMC
37
2
FITB
36
3
BIIB
36
8
MAC
53
5
ACN
54
2
HBI
53
4
PM
49
8
ADBE
50
3
GME
61
2
EQT
47
13
MA
60
5
HAL
40
11
EMR
57
7
WBA
41
3
ADT
12
2
D
32
10
INTU
54
2
MU
42
14
JNPR
59
3
PLD
35
5
OMC
37
2
FITB
36
3
BIIB
36
8
MAC
53
5
ACN
54
2
HBI
53
4
PM
49
8
ADBE
50
3
GME
61
2
EQT
47
13
MA
60
5
Financhill
Back

Theriva Biologics Quote, Financials, Valuation and Earnings

2025 Gold Forecast: A Perfect Storm for Demand

Discover our Gold Price Outlook for 2025--FREE--here
Sell
27

TOVX
Theriva Biologics

Last Price:
$1.15
Seasonality Move:
27.37%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump's Legacy-Defining Momentor Strike

But the Surprising Way Trump Solves it Could Cement His Legacy.

Theriva Biologics Price Quote

$1.15
+0.01 (+0%)
(Updated: December 21, 2024 at 6:40 PM ET)

Theriva Biologics Key Stats

Sell
27
Theriva Biologics (TOVX) is a Sell
Day range:
$1.14 - $1.19
52-week range:
$1.14 - $17.11
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.90
P/B ratio:
0.13%
Volume:
48.5K
Avg. volume:
130.7K
1-year change:
-91.69%
Market cap:
$3.2M
Revenue:
$0
EPS:
$-33.18

How Much Does Theriva Biologics Make?

Data Unavailable

Is Theriva Biologics Growing As A Company?

Data Unavailable

Theriva Biologics Stock Price Performance

  • Did Theriva Biologics Stock Go Up Last Month?
    Theriva Biologics share price went down by -9.52% last month
  • Did TOVX's Share Price Rise Over The Last Year?
    TOVX share price fell by -91.69% over the past 1 year

What Is Theriva Biologics 52-Week High & Low?

Theriva Biologics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Theriva Biologics?

Data Unavailable

Is Theriva Biologics Cash Flow Positive?

Data Unavailable

Theriva Biologics Return On Invested Capital

Data Unavailable

Theriva Biologics Earnings Date & Stock Price

Theriva Biologics Competitors

  • Who Are Theriva Biologics's Competitors?
    Below is a list of companies who compete with Theriva Biologics or are related in some way:
    • iBio Inc (IBIO)
    • Merck & Co Inc (MRK)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Pro-Dex Inc (PDEX)
    • Palatin Technologies Inc (PTN)

Theriva Biologics Dividend Yield

Data Unavailable

Theriva Biologics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -29.71%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 100.00
Upside from Last Price: 8671.93%

Major Shareholders

Data Unavailable